Table 2.

Lipofuscin scoring in CPA tissuses (with and without the PRKACA mutation) compared to positive (PPNAD) and negative controls (Conn adenoma and peritumoral tissues).

Tissues	Sample numbers	Number of lipofuscin granules per slide (mean±SD)	Presence of lipofuscin†	Statistcal significance (p)
CPAs	10	46.9±9.5	+++	p*=0.0001
PRKACA somatic mutation	4	53.5±55.8	+++	p**=0.145
No PPKACA mutation	6	28.2±56.8	++
PPNADs	3	73.3±109.76	+++	p***=0.89
Peritumoral tissues	5	1.6±1.8	−
Conn adenoma	4	3.8±4.8	−

^†Grading of lipofuscin pigmentation in H & E staining slides: intense (+++) ≥40 lipofuscin-pigment granules per slide; moderate (++)=20–40; faint (+)=10–20; negative (–) ≤10

^*Comparison of the number of lipofuscin granules per slide of CPAs (n=10 tissues) tissues vs. Conn adenomas (n=4) and peritumoral tissues (n=5)

^***Comparison of the number of lipofuscin granules per slide of PPNAD (n=3) tissues vs. CPAs tissues (n=10); CPAs: Cortisol producing adenomas; PPNAD: Primary pigmented nodular adrenocortical disease